{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:52:35Z","timestamp":1760608355721},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"suppl_4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1093\/rheumatology\/kel314","type":"journal-article","created":{"date-parts":[[2006,9,16]],"date-time":"2006-09-16T08:35:27Z","timestamp":1158395727000},"page":"iv22-iv25","source":"Crossref","is-referenced-by-count":22,"title":["Pulmonary arterial hypertension and rheumatic diseases\u2014from diagnosis to treatment"],"prefix":"10.1093","volume":"45","author":[{"given":"O.","family":"Distler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Pignone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2006,10]]},"reference":[{"key":"key\n\t\t\t\t20170703104200_B1","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/j.ehj.2004.09.014","article-title":"Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The task force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology","volume":"25","author":"Galie","year":"2004","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170703104200_B2","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1002\/art.21131","article-title":"The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study)","volume":"52","author":"Wigley","year":"2005","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20170703104200_B3","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1136\/ard.62.11.1088","article-title":"Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach","volume":"62","author":"Mukerjee","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20170703104200_B4","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1191\/0961203303lu1051oa","article-title":"Pulmonary hypertension in systemic lupus","volume":"13","author":"Johnson","year":"2004","journal-title":"Lupus"},{"key":"key\n\t\t\t\t20170703104200_B5","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/rheumatology\/35.10.989","article-title":"Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients","volume":"35","author":"Koh","year":"1996","journal-title":"Br J Rheumatol"},{"key":"key\n\t\t\t\t20170703104200_B6","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1378\/chest.123.2.344","article-title":"Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis","volume":"123","author":"Kawut","year":"2003","journal-title":"Chest"},{"key":"key\n\t\t\t\t20170703104200_B7","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1161\/hc4801.100076","article-title":"Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects","volume":"104","author":"McQuillan","year":"2001","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170703104200_B8","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/rheumatology\/keh067","article-title":"Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis","volume":"43","author":"Mukerjee","year":"2004","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t20170703104200_B9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1378\/chest.126.1_suppl.14S","article-title":"Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines","volume":"126","author":"McGoon","year":"2004","journal-title":"Chest"},{"key":"key\n\t\t\t\t20170703104200_B10","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1093\/eurheartj\/ehi891","article-title":"Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension","volume":"27","author":"Williams","year":"2006","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170703104200_B11","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1002\/art.11345","article-title":"N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers","volume":"48","author":"Allanore","year":"2003","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20170703104200_B12","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/art.10775","article-title":"Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement","volume":"48","author":"Steen","year":"2003","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20170703104200_B13","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kel273","article-title":"Need for improved outcome measures in pulmonary arterial hypertension related to systemic sclerosis","author":"Distler","year":"2006","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t20170703104200_B14","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/ard.2004.026427","article-title":"Pulmonary arterial hypertension in systemic sclerosis: diagnostic pathway and therapeutic approach","volume":"64","author":"Robertson","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20170703104200_B15","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1136\/ard.2004.029074","article-title":"Effect of steroid pulse therapy on mixed connective tissue disease with pulmonary arterial hypertension","volume":"64","author":"Kamata","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20170703104200_B16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1191\/0961203304lu509oa","article-title":"Therapy with intermittent pulse cyclophosphamide for pulmonary hypertension associated with systemic lupus erythematosus","volume":"13","author":"Gonzalez-Lopez","year":"2004","journal-title":"Lupus"},{"key":"key\n\t\t\t\t20170703104200_B17","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/01.CIR.70.4.580","article-title":"Primary pulmonary hypertension: natural history and the importance of thrombosis","volume":"70","author":"Fuster","year":"1984","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170703104200_B18","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1161\/CIRCULATIONAHA.104.488486","article-title":"Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension","volume":"111","author":"Sitbon","year":"2005","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170703104200_B19","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/thx.54.3.273","article-title":"Treatment of pulmonary hypertension secondary to connective tissue diseases","volume":"54","author":"Sanchez","year":"1999","journal-title":"Thorax"},{"key":"key\n\t\t\t\t20170703104200_B20","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group","volume":"334","author":"Barst","year":"1996","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170703104200_B21","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20170703104200_B22","doi-asserted-by":"crossref","first-page":"149","DOI":"10.7326\/0003-4819-144-2-200601170-00026","article-title":"Inhaled treprostinil [corrected] for treatment of chronic pulmonary arterial hypertension","volume":"144","author":"Voswinckel","year":"2006","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20170703104200_B23","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1378\/chest.129.3.683","article-title":"Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial","volume":"129","author":"Tapson","year":"2006","journal-title":"Chest"},{"key":"key\n\t\t\t\t20170703104200_B24","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1056\/NEJM200006223422503","article-title":"Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue","volume":"342","author":"Hoeper","year":"2000","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170703104200_B25","doi-asserted-by":"crossref","first-page":"282","DOI":"10.7326\/0003-4819-143-4-200508160-00009","article-title":"Evaluation and management of the patient with pulmonary arterial hypertension","volume":"143","author":"Rubin","year":"2005","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20170703104200_B26","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0735-1097(02)01786-2","article-title":"Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial","volume":"39","author":"Galie","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170703104200_B27","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S0012-3692(15)50417-0","article-title":"Effects of lipo-prostaglandin E1 on pulmonary hemodynamics and clinical outcomes in patients with pulmonary arterial hypertension","volume":"128","author":"Shen","year":"2005","journal-title":"Chest"},{"key":"key\n\t\t\t\t20170703104200_B28","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jacc.2005.04.050","article-title":"Ambrisentan therapy for pulmonary arterial hypertension","volume":"46","author":"Galie","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170703104200_B29","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.jacc.2006.01.057","article-title":"Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan","volume":"47","author":"Barst","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170703104200_B30","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/0140-6736(91)92033-X","article-title":"Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension","volume":"338","author":"Pepke-Zaba","year":"1991","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170703104200_B31","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Galie","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170703104200_B32","first-page":"1488","article-title":"Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study","volume":"44","author":"Ghofrani","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170703104200_B33","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0735-1097(03)00555-2","article-title":"Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension","volume":"42","author":"Ghofrani","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170703104200_B34","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1378\/chest.123.4.1293","article-title":"Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension","volume":"123","author":"Stiebellehner","year":"2003","journal-title":"Chest"},{"key":"key\n\t\t\t\t20170703104200_B35","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1183\/09031936.03.00008003","article-title":"Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids","volume":"22","author":"Hoeper","year":"2003","journal-title":"Eur Respir J"},{"key":"key\n\t\t\t\t20170703104200_B36","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1164\/rccm.200210-1212OC","article-title":"Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension","volume":"168","author":"Marcos","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20170703104200_B37","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1172\/JCI17500","article-title":"Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension","volume":"111","author":"Petkov","year":"2003","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t20170703104200_B38","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/01.CIR.0000087592.47401.37","article-title":"Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells","volume":"108","author":"Nishimura","year":"2003","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170703104200_B39","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1378\/chest.129.2.417","article-title":"Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension","volume":"129","author":"Klinger","year":"2006","journal-title":"Chest"},{"key":"key\n\t\t\t\t20170703104200_B40","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMc051946","article-title":"Imatinib for the treatment of pulmonary arterial hypertension","volume":"353","author":"Ghofrani","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170703104200_B41","article-title":"Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension","author":"Bargagli","year":"2005","journal-title":"Respiration"},{"key":"key\n\t\t\t\t20170703104200_B42","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1253\/circj.70.174","article-title":"Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension","volume":"70","author":"Ishikura","year":"2006","journal-title":"Circ J"},{"key":"key\n\t\t\t\t20170703104200_B43","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1172\/JCI23203","article-title":"Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension","volume":"115","author":"McMurtry","year":"2005","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t20170703104200_B44","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1165\/rcmb.2005-0115OC","article-title":"Microvascular regeneration in established pulmonary hypertension by angiogenic gene transfer","volume":"35","author":"Zhao","year":"2006","journal-title":"Am J Respir Cell Mol Biol"},{"key":"key\n\t\t\t\t20170703104200_B45","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2174\/157016106775203090","article-title":"The influence of sex hormones on pulmonary vascular reactivity: possible vasodilator therapies for the treatment of pulmonary hypertension","volume":"4","author":"Smith","year":"2006","journal-title":"Curr Vasc Pharmacol"},{"key":"key\n\t\t\t\t20170703104200_B46","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1527-3466.2005.tb00174.x","article-title":"Hypoxic pulmonary hypertension (HPH) and iptakalim, a novel ATP-sensitive potassium channel opener targeting smaller arteries in hypertension","volume":"23","author":"Wang","year":"2005","journal-title":"Cardiovasc Drug Rev"},{"key":"key\n\t\t\t\t20170703104200_B47","first-page":"277","article-title":"The treatment of diffuse cutaneous systemic sclerosis with autologous hemopoietic stem cells transplantation (HSCT): our experience on 2 cases","volume":"57","author":"Miniati","year":"2005","journal-title":"Reumatismo"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/45\/suppl_4\/iv22\/18096449\/kel314.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T06:28:57Z","timestamp":1503556137000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-lookup\/doi\/10.1093\/rheumatology\/kel314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":47,"journal-issue":{"issue":"suppl_4","published-online":{"date-parts":[[2006,10]]},"published-print":{"date-parts":[[2006,10]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/kel314","relation":{},"ISSN":["1462-0332","1462-0324"],"issn-type":[{"type":"electronic","value":"1462-0332"},{"type":"print","value":"1462-0324"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}